Showing 3951-3960 of 5771 results for "".
- LumiThera Acquires Diopsys, Provider of Light-Based Theranostic Approach to Treat Ocular Diseasehttps://modernod.com/news/lumithera-acquires-diopsys-provider-of-light-based-theranostic-approach-to-treat-ocular-disease/2480430/LumiThera announced its entry into a definitive merger agreement with Diopsys, a provider of modern visual electrophysiology medical devices that help eye care professionals analyze the entire visual pathway for visual and neuro-visual disorders. Under the terms of
- Jim Mazzo Joining Board of Directors at TearLabhttps://modernod.com/news/jim-mazzo-joining-board-of-directors-at-tearlab/2480423/TearLab announced the addition of James V. Mazzo to the company's Board of Directors.
- CXL Ophthalmics to Present Phase 2 Clinical Trial Results in Epi-On Cross-linking on November 14 at American Academy of Ophthalmologyhttps://modernod.com/news/cxl-ophthalmics-to-present-phase-2-clinical-trial-results-in-epi-on-cross-linking-on-november-14-at-american-academy-of-ophthalmology/2480421/CXL Ophthalmics announced that the results of CXL-005, a phase 2 Trial in transepithelial (Epi-On) cross-linking, will be featured in the “Hot Topics 2021” session at AAO on November
- Alcon Unveils SMART Solutions Integration and Connectivity Platform at AAO 2021https://modernod.com/news/alcon-unveils-latest-evolution-of-cataract-integration-and-connectivity-at-aao-2021/2480414/At the American Academy of Ophthalmology (AAO) 2021 annual meeting in New Orleans, Alcon will feature its latest advancement in integrated and connected surgical technologi
- Alcon to Acquire Ivantis, Maker of the Hydrus Microstent for Surgical Glaucomahttps://modernod.com/news/alcon-to-acquire-ivantis-and-its-hydrus-microstent-for-surgical-glaucoma-strengthening-global-ophthalmology-portfolio/2480410/Alcon announced its intention to acquire Ivantis, developer and manufacturer of the Hydrus Microstent. The deal will strenghten Alcon's surgical glaucoma portfolio and allow it to enter the growing MIGS category. Under terms of the deal, Alcon will pay $475 million in upfr
- Retina and Glaucoma Experts to Present Best Practices Using Iridex Technologies During Consensus Panel and AAOhttps://modernod.com/news/retina-and-glaucoma-experts-to-present-best-practices-using-iridex-technologies-during-consensus-panel-and-aao/2480409/Iridex announced that an international consensus panel of ten glaucoma experts will discuss MicroPulse Transscleral Laser Therapy an
- I-MED Pharma Set to Launch its Dry Eye Product Portfolio in the UShttps://modernod.com/news/i-med-pharma-set-to-launch-its-innovative-dry-eye-product-portfolio-in-the-us/2480408/I-MED Pharma USA announced it is bringing its dry eye product portfolio to the US market and will sell directly to eye care professionals. The dry eye portfolio includes I-DROP artificial tears, I-LID ’N LASH ocular hy
- Tarsus Pharmaceuticals Presents Data from Two Studies on the Prevalence and Impact of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-presents-data-from-two-studies-on-the-prevalence-and-impact-of-demodex-blepharitis/2480402/Tarsus Pharmaceuticals presented data today from two pioneering studies on the prevalence and impact of Demodex blepharitis at the American Academy of Optometry (AAOpt) 2021 Annual Meeting in Boston. The Titan real-world prevalence study data revealed that Demodex blepharitis accounts for ov
- Oyster Point’s Tyrvaya Nasal Spray for Dry Eye Disease is Now Available at US Regional Wholesalershttps://modernod.com/news/oyster-points-tyrvaya-nasal-spray-for-dry-eye-disease-is-now-available-at-us-regional-wholesalers/2480399/Oyster Point Pharma announced that Tyrvaya (varenicline solution) Nasal Spray 0.03 mg is now available at US regional wholesalers for distribution to pharmacies. The FDA approved Tyrvaya Nasal Spray for the treatment of the signs and symptoms of dry eye disease on O
- Prism Vision Group Acquires Three New Practiceshttps://modernod.com/news/prism-vision-group-acquires-three-new-practices/2480398/PRISM Vision Group announced that it has recently acquired Bethlehem Eye Associates in Bethlehem, Pennsylvania; Schefkind Eye Care with two locations in Alexandria, Virginia; and Carabin Eye Care in New Milford, New Jersey. Terms of the deals were not disclosed.